[Irradiation of cerebral gliomas, advantages of synthetic ACTH (synacthen) (author's transl)].
D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001254:Astrocytoma / Q000000981:diagnostic imaging / Q000532:radiotherapy; D001929:Brain Edema / Q000209:etiology / Q000517:prevention & control; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D004806:Ependymoma / Q000000981:diagnostic imaging; D005260:Female; D005909:Glioblastoma / Q000532:radiotherapy; D005910:Glioma / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008527:Medulloblastoma / Q000532:radiotherapy; D008875:Middle Aged; D009837:Oligodendroglioma / Q000532:radiotherapy; D011859:Radiography; D011878:Radiotherapy / Q000009:adverse effects
D000324:Adrenocorticotropic Hormone
Irradiation des gliomes cérébraux. Intérêt de l'ACTH de synthèse (synacthène.